Title : Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network.

Pub. Date : 2022 Mar

PMID : 34837569






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: We identified 9766 patients with ax-SpA (924 AS and 8842 nr-SpA) and 691,862 without SpA who had COVID-19. Amoxicillin surfactant protein A1 Homo sapiens
2 In the unmatched comparison, patients with ax-SpA had higher risk ratios (RR) for all outcomes. Amoxicillin surfactant protein A1 Homo sapiens
3 Only the risk of VTE was higher in ax-SpA patients (RR: 1.219 (1.037-1.433), p = 0.016). Amoxicillin surfactant protein A1 Homo sapiens
4 Amongst the ax-SpA group, males had worse outcomes in 9 out of the 11 domains except for VTE and cerebral infarction, while blacks had worse outcomes in all except for mortality and the need for renal replacement therapy. Amoxicillin surfactant protein A1 Homo sapiens
5 Ax-SpA patients who had been prescribed non-steroidal anti-inflammatory drugs in the 3 months prior to COVID-19 had poorer outcomes. Amoxicillin surfactant protein A1 Homo sapiens
6 CONCLUSION: In conclusion, COVID-19 outcomes were better in patients with ax-SpA as compared with PS matched controls except for increased risk for VTE. Amoxicillin surfactant protein A1 Homo sapiens